These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36655869)

  • 1. Cost-effectiveness of different monitoring strategies in a screening and treatment programme for hepatitis B in The Gambia.
    Schmit N; Nayagam S; Lemoine M; Ndow G; Shimakawa Y; Thursz MR; Hallett TB
    J Glob Health; 2023 Jan; 13():04004. PubMed ID: 36655869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis.
    Nayagam S; Conteh L; Sicuri E; Shimakawa Y; Suso P; Tamba S; Njie R; Njai H; Lemoine M; Hallett TB; Thursz M
    Lancet Glob Health; 2016 Aug; 4(8):e568-78. PubMed ID: 27443782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treat All versus targeted strategies to select HBV-infected people for antiviral therapy in The Gambia, west Africa: a cost-effectiveness analysis.
    Nguyen LBL; Lemoine M; Ndow G; Ward ZJ; Hallet TB; D'Alessandro U; Thursz M; Nayagam S; Shimakawa Y
    Lancet Glob Health; 2024 Jan; 12(1):e66-e78. PubMed ID: 38097300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modelling cost-effectiveness of tenofovir for prevention of mother to child transmission of hepatitis B virus (HBV) infection in South Africa.
    Mokaya J; Burn EAO; Tamandjou CR; Goedhals D; Barnes EJ; Andersson M; Pinedo-Villanueva R; Matthews PC
    BMC Public Health; 2019 Jun; 19(1):829. PubMed ID: 31242901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost-effectiveness of universal hepatitis B screening for reaching WHO diagnosis targets in Australia by 2030.
    Xiao Y; Hellard ME; Thompson AJ; Seaman C; Howell J; Scott N
    Med J Aust; 2023 Mar; 218(4):168-173. PubMed ID: 36596568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients.
    Yuan Y; Iloeje UH; Hay J; Saab S
    J Manag Care Pharm; 2008; 14(1):21-33. PubMed ID: 18240879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of treating all hepatitis B-positive individuals in the United States.
    Razavi-Shearer D; Estes C; Gamkrelidze I; Razavi H
    J Viral Hepat; 2023 Sep; 30(9):718-726. PubMed ID: 37260095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective.
    Veldhuijzen IK; Toy M; Hahné SJ; De Wit GA; Schalm SW; de Man RA; Richardus JH
    Gastroenterology; 2010 Feb; 138(2):522-30. PubMed ID: 19879275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence to chronic hepatitis B treatment guideline recommendations for laboratory monitoring of patients who are not receiving antiviral treatment.
    Juday T; Tang H; Harris M; Powers AZ; Kim E; Hanna GJ
    J Gen Intern Med; 2011 Mar; 26(3):239-44. PubMed ID: 20978862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cost-effectiveness of community-based treatment of chronic hepatitis B in China].
    Zhang SX; Yang PC; Cai YL; Lin Y; Zou YH
    Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Jul; 38(7):860-867. PubMed ID: 28738456
    [No Abstract]   [Full Text] [Related]  

  • 12. Recognizing the impact of endemic hepatitis D virus on hepatitis B virus eradication.
    Goyal A; Murray JM
    Theor Popul Biol; 2016 Dec; 112():60-69. PubMed ID: 27594346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness Analysis of Alternative Antiviral Strategies for the Treatment of HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B in the United Kingdom.
    Bermingham SL; Hughes R; Fenu E; Sawyer LM; Boxall E; T Kennedy P; Dusheiko G; Hill-Cawthorne G; Thomas H
    Value Health; 2015 Sep; 18(6):800-9. PubMed ID: 26409607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation.
    Su S; Wong WC; Zou Z; Cheng DD; Ong JJ; Chan P; Ji F; Yuen MF; Zhuang G; Seto WK; Zhang L
    Lancet Glob Health; 2022 Feb; 10(2):e278-e287. PubMed ID: 35063115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tenofovir disoproxil fumarate in pregnancy for prevention of mother to child transmission of hepatitis B in a rural setting on the Thailand-Myanmar border: a cost-effectiveness analysis.
    Bierhoff M; Angkurawaranon C; Rijken MJ; Sriprawa K; Kobphan P; Nosten FN; van Vugt M; McGready R; Devine A
    BMC Pregnancy Childbirth; 2021 Feb; 21(1):157. PubMed ID: 33618698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation of hepatitis B vaccination in low-income countries: using cost-effectiveness affordability curves.
    Kim SY; Salomon JA; Goldie SJ
    Bull World Health Organ; 2007 Nov; 85(11):833-42. PubMed ID: 18038073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis.
    Thompson Coon J; Rogers G; Hewson P; Wright D; Anderson R; Cramp M; Jackson S; Ryder S; Price A; Stein K
    Health Technol Assess; 2007 Sep; 11(34):1-206. PubMed ID: 17767898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis.
    Kanwal F; Gralnek IM; Martin P; Dulai GS; Farid M; Spiegel BM
    Ann Intern Med; 2005 May; 142(10):821-31. PubMed ID: 15897532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementation of an in-house quantitative real-time polymerase chain reaction method for Hepatitis B virus quantification in West African countries.
    Ghosh S; Sow A; Guillot C; Jeng A; Ndow G; Njie R; Toure S; Diop M; Mboup S; Kane CT; Lemoine M; Thursz M; Zoulim F; Mendy M; Chemin I
    J Viral Hepat; 2016 Nov; 23(11):897-904. PubMed ID: 27353593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of hepatitis B mother-to-child transmission in Namibia: A cost-effectiveness analysis.
    Tamandjou Tchuem CR; Andersson MI; Wiysonge CS; Mufenda J; Preiser W; Cleary S
    Vaccine; 2021 May; 39(23):3141-3151. PubMed ID: 33962836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.